Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cabaletta Bio ( (CABA) ) just unveiled an update.
On October 29, 2025, Cabaletta Bio released an updated corporate presentation outlining their progress in developing rese-cel, a CD19-CAR T cell therapy for autoimmune diseases. The company plans to initiate a myositis registrational cohort in the fourth quarter of 2025 and has completed enrollment in Phase 1/2 trials for other conditions, highlighting their commitment to advancing clinical trials and potential market opportunities.
The most recent analyst rating on (CABA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Underperform.
Cabaletta Bio’s overall score is low primarily due to its financial performance, marked by no revenue and increasing losses. The technical analysis indicates a bearish trend, further impacting the score. However, the recent positive clinical trial data provides a glimmer of hope, slightly improving future outlook. Despite this, the stock’s valuation remains a concern, making it a risky investment at this stage.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio, Inc. operates in the biotechnology industry, focusing on developing targeted cellular therapies for autoimmune diseases. The company is advancing its pipeline with rese-cel, a CD19-CAR T cell therapy, aiming to provide transformative clinical responses for patients with conditions like myositis, lupus nephritis, and systemic sclerosis.
Average Trading Volume: 2,818,788
Technical Sentiment Signal: Hold
Current Market Cap: $250.6M
See more data about CABA stock on TipRanks’ Stock Analysis page.